Sinopharm Modern Pharmaceutical Co., Ltd. Brand Ranking
If you want to improve the ranking of your company brand or wish to avoid appearing here, please contact trading@bossgoo.com.
Sinopharm Modern Pharmaceutical Co., Ltd.

Sinopharm Modern Pharmaceutical Co., Ltd.

Sinopharm Group Co., Ltd.
If you want to improve the ranking of your company brand or wish to avoid appearing here, please contact trading@bossgoo.com.
Brand Introduction

Shanghai Modern Pharmaceutical Co., Ltd. (hereinafter referred to as "Sino Pharmaceutical Modern") was established in 1996. It is a high-tech enterprise in the pharmaceutical industry founded by an academician of the Chinese Academy of Engineering and specializing in the research, development, production and sales of pharmaceutical products. The company was listed on the Shanghai Stock Exchange on June 16, 2004 (code: 600420, referred to as Sinopharm Hyundai). In April 2010, he joined China Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Sino Pharmaceutical Group").

Sinopharm Modern serves the national strategy of "Healthy China", with the development goal of achieving innovation-driven, sustainable development, strengthening, improving and expanding state-owned capital, and building high-quality chemical pharmaceuticals as the main body, and biopharmaceuticals and big health as the two wings." The strategic pattern is the focus of the task, adhere to the corporate philosophy of Sinopharm Group's "protecting life and caring for health", focuses on the five major areas of "anti-infection, cardiovascular and cerebrovascular, anti-tumor and immune regulation, metabolism and endocrine, and anesthesia spirit", and coordinates and optimizes the industrial layout. With multi-wheel drive, we are committed to becoming an innovation-driven and cutting-edge pharmaceutical company, and becoming a dynamic, powerful and influential industry guide. Sinopharm Modern is positioned as a unified chemical pharmaceutical industry under Sinopharm Group The platform has 23 wholly owned and controlled subsidiaries, including 15 second-level subsidiaries and 8 third-level subsidiaries. It has formed a professional with unified strategic integrity, concentrated resources, reasonable allocation, scale effect and industrial chain linkage effect The strategic development pattern of the main business revenue exceeds 10 billion.

Recommend Related Products

版权所有 © 宁波全贸信息技术有限公司 浙ICP备12012821号-1 浙B2-20200628

浙公网安备 33020902000078号